A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. The agent of choice for controlling this vomiting is :
## **Core Concept**
Cisplatin is a chemotherapy medication known to cause severe emesis, particularly on the first few days of treatment. The management of chemotherapy-induced nausea and vomiting (CINV) involves various antiemetic agents targeting different pathways.
## **Why the Correct Answer is Right**
The correct answer, , is a second-generation 5-HT3 receptor antagonist or a similar potent antiemetic. Cisplatin-induced emesis is primarily mediated through the release of serotonin (5-HT3) from the small intestine, which then stimulates the vagus nerve and triggers the vomiting reflex. 5-HT3 antagonists like ondansetron are highly effective in controlling acute emesis. However, for delayed emesis (beyond 24 hours), agents like aprepitant, a substance P/neurokinin 1 (NK1) receptor antagonist, are often used in combination with 5-HT3 antagonists and dexamethasone.
## **Why Each Wrong Option is Incorrect**
- **Option A:** is incorrect because, although it might have some antiemetic effects, it is not the most effective agent for controlling cisplatin-induced vomiting.
- **Option B:** is incorrect because, while it could be part of the antiemetic regimen, it is not specified as the agent of choice for intractable vomiting on the third day of cisplatin therapy.
- **Option D:** is incorrect because it does not directly address the acute and delayed emesis effectively as the correct option does.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is the classification of emesis: acute (within 24 hours) and delayed (>24 hours). For cisplatin, which causes both, a combination of a 5-HT3 antagonist (or similar), an NK1 antagonist, and a corticosteroid like dexamethasone is often used. The use of for preventing CINV, especially in combination therapy, has significantly improved control over nausea and vomiting.
## **Correct Answer:** .